Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Friday November 13, 2009 are:

**************************************************************

EMKR, EMCORE Corporation

EMKR provides compound semiconductor-based components and subsystems for the broadband, fiber optic, satellite, and terrestrial solar power markets. EMKR is the world’s largest manufacturer of highly efficient radiation hard solar cells for space power applications.

** EMKR has been awarded a contract by Dutch Space of Leiden, The Netherlands to manufacture, test, and deliver the solar panels to power the Cygnus’ spacecraft being developed by Orbital Sciences Corporation for NASA’s Commercial Resupply Service project.

The total value of the contract would be in excess of $15 million.

More about EMKR

DrStockPick.com Stock Report!

Tuesday September 15, 2009

**************************************************************

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug candidate that inhibits the sodium glucose transporter 2 (SGLT2). LX4211 is Lexicon’s fourth drug candidate currently being tested in Phase 2 clinical trials.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT),

Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company focused on developing breakthrough treatments for a variety of human diseases, recently announced that it successfully completed a second Phase 1 clinical trial of LX1032. The drug candidate will be used by patients to manage gastrointestinal symptoms associated with carcinoid syndrome, which is a chronic condition that results in metastatic neuroendocrine tumors that secrete large amounts of serotonin.

During the Phase 1b multiple ascending-dose trial, the LX1032 was found to be well-tolerated at all dosage levels by all 40 volunteers. Five doses were given to the participants ranging from 100 mg to a maximum dosage of 1500 mg over a 14-day period. Analysis of the data found that LX1032 significantly reduced blood serotonin levels and urinary 5-HIAA, a market of serotonin biosynthesis. No serious adverse effects were reported by the volunteers of the trial.

“The substantial reduction in serotonin observed in this study confirms